An Independent Review
Home About Us Contact Us Index Search Consumer Topics Back Issues

Subject Index: Australian Prescriber Volumes 17 to current (1994-2008)

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

To find a reference on this page either scroll or hold down the "Ctrl" key and press "f".

nadroparin
  • Fraxiparin Forte (New strength) 22(5) 125-7
    		•
  • low molecular weight heparin - Fraxiparine (New drug) 19(2) 38-40
    		•
  • in thromboembolism 19(4) 104-8
    		•
    nafarelin
  • endometriosis - Synarel (New drug) 17(2) 30-2
    		•
    nail infections
  • amorolfine - antifungal - Loceryl (New drug) 19(1) 24-7
    		•
  • antifungal drugs 19(3) 72-5
    		•
  • terbinafine and fungal toenails (PBAC question) 22(6) 135
    		•
  • (letter) 23(4) 72
    		•
    naltrexone
  • in alcohol dependence 25(3) 70-3
    		•
  • opioid and alcohol dependence - ReVia (New drug) 22(2) 43-7
    		•
  • letter 22(5) 103-5
    		•
  • in opioid dependence 24(1) 4-6
    		•
    Naprosyn
  • see naproxen 25(5) 104-7
    		•
    naproxen
  • discontinuation of naproxen suspension (letter) 25(5) 104-7
    		•
    naproxen sodium
  • Crysanal (New brand) 23(1) 21-3
    		•
  • Nurolasts (New formulation) 24(4) 100-2
    		•
    Naramig
  • see naratriptan 21(4) 108-11
    		•
    naratriptan
  • migraine - Naramig (New drug) 21(4) 108-11
    		•
    narcolepsy
  • modafinil - Modavigil (New drug) 25(5) 120-3
    		•
    Naropin
  • see ropivacaine 23(4) 84-7; 19(2) 38-40
    		•
    nasal decongestants
  • over-the-counter medicines and children 24(6) 149-51
    		•
  • letter 25(2) 27-8
    		•
  • in sinusitis 23(2) 39-42
    		•
  • letter 23(5) 93-6
    		•
    Nasonex
  • see mometasone 22(5) 125-7
    		•
    natalizumab
  • Tysabri - multiple sclerosis (New drug) 30(4) 107-11
    		•
    National Drugs and Poisons Schedule
  • Committee 20(1) 12-3
    		•
    National Medicines Policy
  • Aboriginal people 26(5) 106-9
    		•
  • letter 27(3) 55-7
    		•
  • National Prescribing Service (editorial) 25(2) 26-7
    		•
  • prescribing issues for Aboriginal people 26(5) 106-9
    		•
  • quality use of generic drugs (editorial) 27(4) 80-1
    		•
  • letters 28(2) 29-33; 27(6) 138-41
    		•
  • quality use of medicines (editorial) 24(5) 106-7
    		•
    National Prescribing Service
  • editorial 21(2) 30-1
    		•
  • outsourcing of Australian Prescriber (editorials) 25(2) 26-7; 25(1) 2
    		•
  • telephone information services
  • Medicines Line 26(4) 90; 25(5) 115
    		•
  • Therapeutic Advice and Information Service (TAIS) 26(4) 90; 23(4) 78
    		•
    Natrilix
  • see indapamide 22(5) 125-7
    		•
    natriuretic peptide, B-type
  • cardiac markers - abnormal laboratory results 26(4) 88-90
    		•
  • congestive heart failure - abnormal laboratory results 26(3) 64-5
    		•
    nausea
  • aprepitant - Emend - cancer chemotherapy (New drug) 27(3) 76-9
    		•
  • granisetron - Kytril (New drug) 27(4) 101-5
    		•
    Navelbine
  • see vinorelbine 21(4) 87-91; 21(2) 49-55
    		•
    Navoban
  • see tropisetron 17(4) 87-90
    		•
    nebulisers
  • asthma inhalation devices 26(1) 5-7
    		•
  • tropical climates (letter) 26(4) 75-7
    		•
    necrosis
  • spider bites 29(6) 156-8
    		•
    nedocromil
  • asthma - Tilade (New drug) 18(2) 35-8
    		•
  • Tilade CFC-Free (New formulation) 24(3) 71-5
    		•
    needles
  • letters 22(2) 28-31; 21(3) 60-3
    		•
  • needle-stick injuries 24(4) 98-100
    		•
    nefazodone
  • antidepressant - Serzone (New drug) 20(3) 77-9
    		•
  • letter 21(1) 5-8
    		•
  • pharmacology of serotonin reuptake inhibitors 22(5) 106-8
    		•
    NeisVac-C
  • see meningococcal group C conjugate vaccine 26(3) 56-8; 25(6) 147-51
    		•
    nelfinavir
  • HIV - Viracept (New drug) 21(2) 49-55
    		•
    neonatal - see newborn
    Neoral
  • see cyclosporin 21(2) 49-55
    		•
    NeoRecormon
  • see epoetin beta 29(4) 112-5
    		•
    Neotigason
  • see acitretin 18(4) 86-7
    		•
    nephritis, interstitial
  • omeprazole adverse effects 30(3) 67
    		•
    nephrotoxicity
  • common drugs 23(1) 17-9
    		•
    Neulasta
  • see pegfilgrastim 25(6) 147-51
    		•
    neuralgia
  • drug treatment of neuropathic pain 29(3) 72-5
    		•
  • post-herpetic - pregabalin - Lyrica (New drug) 28(3) 75-9
    		•
    neuralgia, trigeminal
  • patient support organisation 29(3) 75
    		•
    neuraminidase inhibitors
  • antiviral drugs and influenza prophylaxis (editorial) 30(2) 30-1
    		•
  • in influenza 25(1) 5-7
    		•
  • oseltamavir - influenza - Tamiflu (New drug) 24(2) 43-7
    		•
    neurokinin antagonists
  • aprepitant - Emend - emetogenic cancer chemotherapy (New drug) 27(3) 76-9
    		•
    neurology
  • magnetic resonance imaging in neuroradiology 31(1) 18-20
    		•
  • Therapeutic Guidelines - book reviews 30(4) 91; 25(6) 141
    		•
    neuromuscular blockade
  • cisatracurium besylate - Nimbex (New drug) 20(2) 45-51
    		•
  • mivacurium chloride - Mivacron (New drug) 19(2) 38-40
    		•
  • rocuronium bromide - Esmeron (New drug) 18(4) 86-7
    		•
    Neurontin
  • see gabapentin 23(5) 110-1; 17(3) 73
    		•
    neuropathic pain
  • anticonvulsants 22(6) 140-1
    		•
  • letter 23(4) 72
    		•
  • drug treatment 29(3) 72-5
    		•
  • dental notes 29(3) 82
    		•
  • pregabalin - Lyrica (New drug) 28(3) 75-9
    		•
    neuropathy
  • drug-induced (letter) 23(4) 72
    		•
  • folates and vitamin B 22(1) 16-8
    		•
    neutropenia
  • in cancer chemotherapy 18(3) 65-7
    		•
  • lenograstim - Granocyte (New drug) 17(2) 30-2
    		•
  • pegfilgrastim - Neulasta (New drug) 25(6) 147-51
    		•
  • quetiapine (medicinal mishap) 31(1) 10-11
    		•
  • voriconazole - febrile neutropenia - Vfend (New drug) 26(4) 94-5
    		•
    nevirapine
  • HIV - Viramune (New drug) 20(4) 101-3
    		•
  • Viramune (New formulation) 24(1) 20-3
    		•
    New Zealand
  • direct-to-consumer advertising (editorial) 29(2) 30-2
    		•
  • health reforms and prescribing budgets (editorial) 20(2) 26-7
    		•
    newborn
  • abnormal laboratory results - paediatric biochemical tests 28(5) 126-9
    		•
  • hearing screening 26(4) 82-4
    		•
  • nitric oxide - neonatal respiratory failure - INOmax (New drug) 31(1) 24-7
    		•
  • poractant alfa - respiratory distress syndrome - Curosurf (New drug) 28(3) 75-9
    		•
    Nexavar
  • see sorafenib 29(6) 167-71
    		•
    Nexium
  • see esomeprazole 27(6) 159-65; 25(4) 94-9
    		•
    nicorandil
  • angina - Ikorel (New drug) 22(1) 20-3
    		•
    Nicorette
  • see nicotine 22(6) 147-51
    		•
    nicotine
  • bupropion (PBAC question) 24(3) 64
    		•
  • bupropion - Zyban (New drug) 24(1) 20-3
    		•
  • distribution in human milk 20(2) 35-40
    		•
  • Nicorette inhaler (New formulation) 22(6) 147-51
    		•
  • varenicline - Champix (New drug) 31(1) 24-7
    		•
    nicotine replacement therapy
  • smoking cessation guidelines 28(3) 73-5
    		•
  • letter 28(6) 136-9
    		•
    Nidem
  • see gliclazide 24(6) 155-8
    		•
    Nifecard
  • see nifedipine 18(1) 7-9
    		•
    nifedipine
  • clinical pharmacology of calcium channel antagonists 20(1) 5-8
    		•
  • dihydropyridines and nocturia 20(1) 3-4
    		•
  • gingival hyperplasia (letter) 17(1) 4-5
    		•
  • new brand - Nifecard 18(1) 7-9
    		•
  • new formulations - Adalat 17(4) 87-90
    		•
  • and risk of myocardial infarction (editorial) 22(1) 2-3; 19(2) 35
    		•
    nilutamide
  • prostate cancer - Anandron (New drug) 20(2) 45-51
    		•
    Nimbex
  • see cisatracurium 20(2) 45-51
    		•
    nitric oxide
  • neonatal respiratory failure - INOmax (New drug) 31(1) 24-7
    		•
    nitrofurantoin
  • risks and benefits (letter) 27(4) 82-3
    		•
    nitroglycerin
  • see glyceryl trinitrate 19(2) 52-4; 18(1) 12
    		•
    nizatidine
  • allergy 23(6) 123
    		•
  • pharmacology 23(3) 57-9
    		•
    nocturia
  • dihydropyridines and urination 20(1) 3-4
    		•
    non-steroidal anti-inflammatory drugs - see anti-inflammatory drugs
    norethisterone oestradiol combination
  • Estalis (New combination) 23(5) 110-1
    		•
  • Estracombi (New strength) 19(2) 38-40
    		•
  • Kliogest (New combination) 19(3) 81-3
    		•
  • Kliovance (New brand) 22(6) 147-51
    		•
  • progestogen-only contraceptives 22(1) 6-8
    		•
    norfloxacin
  • Roxin (New brand) 25(6) 147-51
    		•
    Norplant
  • see levonorgestrel 22(1) 6-8
    		•
    Norprolac
  • see quinagolide 28(6) 156-8
    		•
    Northern Ireland
  • prescriber feedback (editorial) 21(1) 3-4
    		•
    Norvir
  • see ritonavir 20(1) 22-3
    		•
    NovoNorm
  • see repaglinide 23(4) 84-7
    		•
    NovoRapid
  • see insulin aspart 24(1) 20-3; 23(5) 110-1
    		•
    Noxafil
  • see posaconazole 29(3) 84-7
    		•
    NPS - see National Prescribing Service
    NSAIDS - see anti-inflammatory drugs
    nuclear magnetic imaging
  • gadoversetamide - contrast medium - OptiMARK (New drug) 24(3) 71-5
    		•
    nuclear medicine
  • thallium scanning in coronary disease 17(3) 57-61
    		•
    number needed to treat
  • interpreting risks and ratios in clinical trials 31(1) 12-6
    		•
  • risk calculation 23(2) 38
    		•
  • letter 24(3) 51-5
    		•
    Nupentin
  • see gabapentin 27(5) 131-3
    		•
    Nurofen
  • see ibuprofen 25(4) 94-9; 23(6) 137-9
    		•
    Nurolasts
  • see naproxen sodium 24(4) 100-2
    		•
    nurse prescribers
  • competency (editorial) 30(3) 58-9
    		•
  • prescribing (editorial) 30(1) 2-3
    		•
  • letters 31(1) 3-4; 30(4) 88-90
    		•
    nursing homes
  • scabies management 23(2) 33-5
    		•
    nutrition - see diet
    Nyogel
  • see timolol 28(3) 75-9
    		•
    Home     Contact Us     Useful Links     Copyright     Privacy     Web Manager